bioRxivCancer Biology
Plk1 overexpression suppresses tumor development by inducing chromosomal instability
G. de Carcer, S. V. Venkateswaran, L. Salgueiro, A. El Bakkali, K. Somogyi, K. Rowald, P. Montanes, M. Sanclemente, B. Escobar, A. de Martino, N. McGranahan, M. Malumbres, R. Sotillo
Abstract
Polo-like kinase 1 (Plk1) is a protein kinase currently considered as an attractive cancer target due to its critical role in the cell division cycle. Plk1 is overexpressed in a wide spectrum of human tumors, being frequently considered as an oncogene. However, its contribution to tumor development is unclear. Using a new inducible knock-in mouse model we report here that Plk1 overexpression does not favor cell proliferation but rather results in abnormal chromosome segregation and cytokinesis, leading to the formation of polyploid cells with reduced proliferative potential. Mechanistically, these cytokinesis defects correlate with defective loading of Cep55 and ESCRT complexes to the abscission bridge during cytokinesis in a Plk1 kinase-dependent manner. In vivo, elevated levels of Plk1 markedly prevent the development of mammary gland tumors induced either by KrasG12D or Her2, in the presence of increased rates of chromosome instability. In patients, higher Plk1 expression levels are associated with significantly increased overall survival in breast cancer subtypes. These data suggest that, despite the therapeutic benefits of inhibiting Plk1 due to its essential role in tumor cell cycles, Plk1 overexpression has tumor suppressive properties by perturbing mitotic progression and cytokinesis.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer
S. Kandala, L. Voith von Voithenberg, … R. Sotillo·bioRxiv·Jun 16, 2022
- Polo-like kinase 4 (Plk4) potentiates anoikis-resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotype
I. S. Fonseca, C. Horta, … J. Paredes·bioRxiv·Dec 16, 2022
- Chk2 sustains PLK1 activity in mitosis to ensure proper chromosome segregation
E. M. Black, C. A. Ramirez Parrado, … L. Kabeche·bioRxiv·Mar 8, 2024
- Transient genomic instability drives tumorigenesis through accelerated clonal evolution
O. Shoshani, B. Bakker, … D. W. Cleveland·bioRxiv·Nov 17, 2020
- Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics
Y. Gao, E. B. Kabotyanski, … J. M. Rosen·bioRxiv·Jun 16, 2021
- Plk1 inhibition delays mitotic entry revealing prophase-specific changes to the phosphoproteome